Table 1.

Clinical Treatment Outcomes and Serum Biomarkers Within and Between the Treatment Groups

	FMD	Q-SRP	Between Groups
PI       Baseline       2 months       4 months	69.40 ±24.20	76.90 ±17.90	0.28
	12.20 ±19.31 †	10.85 ±10.10 †	0.78
	5.45 ±3.25 †	5.55 ±2.92 †	0.92
BOP       Baseline       2 months       4 months	73.85 ±15.20	72.75 ±26.76	0.87
	17.90 ±9.31 †	15.70 ±9.28 †	0.46
	12.75 ±13.68 †	6.60 ±5.39 †‡	0.07
MGI       Baseline       2 months       4 months	3.30 ±0.47	3.35 ±0.58	0.44
	1.80 ±0.76 †	1.90 ±0.44 †	0.03*
	1.70 ±0.80 †	1.80 ±0.52 †	0.04*
PD       Baseline       2 months       4 months	4.18 ±0.58	4.17 ±0.66	0.99
	2.75 ±0.0.57 †	2.74 ±0.62 †	0.93
	2.60 ±0.52 †‡	2.56 ±0.55 †‡	0.84
CAL       Baseline       2 months       4 months	4.20 ±0.57	4.19 ±0.66	0.99
	3.03 ±0.59 †	3.02 ±0.62 †	0.93
	2.78 ±0.54 †‡	2.74 ±0.55 †‡	0.84
IL-17       Baseline       2 months       4 months	359.39 ±252.27	353.32 ±246.75	0.84
	159.75 ±170.16 †	154.20 ±171.53 †	0.45
	145.75 ±167.49 †‡	139.78 ±163.97 †	0.24
IL-1β       Baseline       2 months       4 months	100.05 ±63.73	96.61 ±27.86	0.53
	60.25 ±32.77 †	70.15 ±20.07 †	0.10
	54.38 ±32.35 †	61.60 ±21.38 †‡	0.28

^† Significant with Baseline

^‡ Significant with 2 Months

Asterisk indicates statistical significance based on P<0.05.